IGFBP3 Cancer Research Results

IGFBP3, Insulin-Like Growth Factor Binding Protein-3: Click to Expand ⟱
Source:
Type:
One of the six members of the IGFBP family, is a key protein in the IGF pathway. IGFBP-3 is the most abundant in the blood circulation. Prostate specific antigen (PSA), which is frequently used as a clinical tumor marker for prostate cancer, cleaves IGFBP-3.

Tumor Types:
IGFBP-3 expression can vary significantly across different cancer types. It is often downregulated in several malignancies, including breast cancer, prostate cancer, colorectal cancer, and lung cancer.
In some cases, low levels of IGFBP-3 are associated with tumor progression and poor clinical outcomes.

Tumor Suppressor Functions:
IGFBP-3 is often considered a tumor suppressor due to its ability to inhibit the actions of IGF-1 and IGF-2, which promote cell proliferation and survival. By binding to IGFs, IGFBP-3 can prevent their interaction with IGF receptors, thereby inhibiting their mitogenic effects.

High levels of IGFBP-3 are generally associated with a favorable prognosis in several cancers. For example, elevated IGFBP-3 levels in breast cancer and prostate cancer have been linked to better survival outcomes.
Conversely, low levels of IGFBP-3 are often associated with aggressive tumor behavior and poorer prognosis.


NA, Not Available: Click to Expand ⟱
none (reserved)

Scientific Papers found: Click to Expand⟱
2711- BBR,    Berberine inhibits the progression of breast cancer by regulating METTL3-mediated m6A modification of FGF7 mRNA
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231 - in-vivo, NA, NA
TumCP↓, TumCI↓, TumCMig↓, Apoptosis↑, FGF↓, IGFBP3↑,
3282- SIL,    Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions
- Review, NA, NA
hepatoP↑, AntiCan↑, TumCMig↓, Hif1a↓, selectivity↑, toxicity∅, *antiOx↑, *Inflam↓, TumCCA↑, P21↑, CDK4↓, NF-kB↓, ERK↓, PSA↓, TumCG↓, p27↑, COX2↓, IL1↓, VEGF↓, IGFBP3↑, AR↓, STAT3↓, Telomerase↓, Cyt‑c↑, Casp↑, eff↝, HDAC↓, HATs↑, Zeb1↓, E-cadherin↑, miR-203↑, NHE1↓, MMP2↓, MMP9↓, PGE2↓, Vim↓, Wnt↓, angioG↓, VEGF↓, *TIMP1↓, EMT↓, TGF-β↓, CD44↓, EGFR↓, PDGF↓, *IL8↓, SREBP1↓, MMP↓, ATP↓, uPA↓, PD-L1↓, NOTCH↓, *SIRT1↑, SIRT1↓, CA↓, Ca+2↑, chemoP↑, cardioP↑, Dose↝, Half-Life↝, BioAv↓, BioAv↓, BioAv↓, toxicity↝, Half-Life↓, ROS↓, FAK↓,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress

ROS↓, 1,  

Mitochondria & Bioenergetics

ATP↓, 1,   MMP↓, 1,  

Core Metabolism/Glycolysis

SIRT1↓, 1,   SREBP1↓, 1,  

Cell Death

Apoptosis↑, 1,   Casp↑, 1,   Cyt‑c↑, 1,   p27↑, 1,   Telomerase↓, 1,  

Transcription & Epigenetics

HATs↑, 1,  

Cell Cycle & Senescence

CDK4↓, 1,   P21↑, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State

CD44↓, 1,   EMT↓, 1,   ERK↓, 1,   FGF↓, 1,   HDAC↓, 1,   IGFBP3↑, 2,   NOTCH↓, 1,   STAT3↓, 1,   TumCG↓, 1,   Wnt↓, 1,  

Migration

CA↓, 1,   Ca+2↑, 1,   E-cadherin↑, 1,   FAK↓, 1,   miR-203↑, 1,   MMP2↓, 1,   MMP9↓, 1,   PDGF↓, 1,   TGF-β↓, 1,   TumCI↓, 1,   TumCMig↓, 2,   TumCP↓, 1,   uPA↓, 1,   Vim↓, 1,   Zeb1↓, 1,  

Angiogenesis & Vasculature

angioG↓, 1,   EGFR↓, 1,   Hif1a↓, 1,   VEGF↓, 2,  

Barriers & Transport

NHE1↓, 1,  

Immune & Inflammatory Signaling

COX2↓, 1,   IL1↓, 1,   NF-kB↓, 1,   PD-L1↓, 1,   PGE2↓, 1,   PSA↓, 1,  

Hormonal & Nuclear Receptors

AR↓, 1,  

Drug Metabolism & Resistance

BioAv↓, 3,   Dose↝, 1,   eff↝, 1,   Half-Life↓, 1,   Half-Life↝, 1,   selectivity↑, 1,  

Clinical Biomarkers

AR↓, 1,   EGFR↓, 1,   PD-L1↓, 1,   PSA↓, 1,  

Functional Outcomes

AntiCan↑, 1,   cardioP↑, 1,   chemoP↑, 1,   hepatoP↑, 1,   toxicity↝, 1,   toxicity∅, 1,  
Total Targets: 67

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress

antiOx↑, 1,  

Core Metabolism/Glycolysis

SIRT1↑, 1,  

Migration

TIMP1↓, 1,  

Immune & Inflammatory Signaling

IL8↓, 1,   Inflam↓, 1,  
Total Targets: 5

Scientific Paper Hit Count for: IGFBP3, Insulin-Like Growth Factor Binding Protein-3
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:0  Cells:%  prod#:%  Target#:417  State#:%  Dir#:2
wNotes=0 sortOrder:rid,rpid

 

Home Page